Radiographic tumor regression as a predictor for pathologic response after neoadjuvant therapy for non–small cell lung cancer
作者
Justin M. Bader,Theresa Ermer,William De Santis,Henna Ragoowansi,Ryan J. Kramer,Emily June Zolfaghari,Elizabeth E. Tremblay,Benjamin J. Resio,Daniel J. Boffa,Justin David Blasberg,Anna S Bader,Sanja Dacic,Gavitt Alida Woodard
出处
期刊:JTCVS open [Elsevier BV] 日期:2026-05-04卷期号:32: 101831-101831被引量:1
Objective: This study evaluated correlations between radiographic tumor response and pathologic response to neoadjuvant therapy in non-small cell lung cancer. Methods: All patients with stage IB-IV non-small cell lung cancer treated with neoadjuvant therapy and surgery between 2015 and 2025 in a large health system were included. Demographics, pathologic, treatment, and radiographic data were collected. Per Response Evaluation Criteria In Solid Tumors 1.1, patients were stratified by radiographic tumor size decrease ≥30% from baseline (objective radiographic response, ORR) versus decrease <30% (radiographic stable disease). Major pathologic response and pathologic complete response (pCR) were determined by pathologist review. Results: = .0025, respectively). Among patients with ORR, 43% (10/23) did not have major pathologic response, reflecting persistent viable tumor in many patients with ORR. Programmed cell death ligand 1 status, tumor histology, and specific neoadjuvant treatments were not associated with radiographic or pathologic response. Conclusions: Radiographic reduction in tumor size and decreased PET SUVmax were significantly associated with pCR after neoadjuvant therapy. Although most patients with ORR attained pCR, viable tumor persisted in some patients with ORR and, conversely, there were some patients who had complete or major pathologic response despite radiographic stability after neoadjuvant therapy. Our findings demonstrate that radiographic response can reflect pathologic response, and with further validation, may provide an objective marker for long-term outcomes.